PI3K inhibitor add-on strategy improve glucocorticoid insensitivity in severe asthma Source: Virtual Congress 2020 – Asthma science: novel targets and mechanisms Year: 2020
Corticosteroids: use and insensitivity in severe asthma Source: Eur Respir Mon 2011; 51: 236-252 Year: 2011
Differential anti-inflammatory effects of budesonide and a p38 MAPK inhibitor AZD7624 on COPD pulmonary cells Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control Year: 2018
Profiling the impact of two JAK inhibitors in a pre-clinical model of allergic asthma Source: Virtual Congress 2020 – Scientific advances in airway pharmacology Year: 2020
Inhaled JAK inhibitor GDC-4379 reduces FeNO in patients with mild asthma Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence Year: 2021
Inhibition of Pim1 kinase, new therapeutic approach in virus-induced asthma exacerbations Source: Eur Respir J 2016; 47: 783-791 Year: 2016
The potent and lung-selective inhaled pan JAK inhibitor TD-8236 limits airway inflammation without affecting systemic immunity in mice Source: International Congress 2019 – Novel targets and mechanisms in asthma Year: 2019
RP6503, a novel and selective PI3K δ/gamma inhibitor, potentiates the effect of steroids in pre-clinical models of COPD Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs Year: 2014
Experience of application the selective phosphodiesterase-4 inhibitor roflumilast in the patient with COPD and the metabolic syndrome Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016
Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019
Efficacy and safety of four doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i), in patients with moderate-to-severe COPD Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights Year: 2019
RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-a and -? selectivity, suppresses COPD inflammation Source: Eur Respir J, 50 (4) 1700188; 10.1183/13993003.00188-2017 Year: 2017
Pharmacologic characterization of GB002, a novel inhaled PDGFR kinase inhibitor in development for pulmonary arterial hypertension (PAH) Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020
Oxidative stress-induced corticosteroid insensitivity is reversed by formoterol via inhibition of PI3K signalling in peripheral blood mononuclear cells from patients with COPD and severe asthma Source: Annual Congress 2011 - Models of disease and drug actions Year: 2011
Inhibition of c-kit tyrosine kinase by sunitinib alleviates airway remodeling in a mouse model of chronic asthma Source: Annual Congress 2009 - Preclinical models in drug development Year: 2009
Pulmonary hypertension in patients treated with Src/Abl kinase inhibitor dasatinib Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011
Specific NFKappaB and Rho-Quinase inhibitors compared to corticosteroid in asthma model in mice Source: International Congress 2017 – Translational studies of lung disease Year: 2017
The novel selective PDE4 inhibitor roflumilast: early onset of efficacy in asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003
Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma Source: Eur Respir J 2010; 35: 750-756 Year: 2010
GRC39815-A novel inhaled ROR?t inhibitor as a potential first in class treatment option for COPD Source: Virtual Congress 2021 – Pharmacology of airway diseases: clinical and laboratory studies Year: 2021